Accession Number:



Novel Small Molecule Inhibitor of Tyk2: Lucrative Therapeutic Target in Lupus

Descriptive Note:

Technical Report,01 Sep 2016,31 Aug 2017

Corporate Author:

SRI International Menlo Park United States

Personal Author(s):

Report Date:


Pagination or Media Count:



This research project is directed at exploring the use of small molecule inhibitors of Tyk2 and Jak1 aimed at ameliorating the chronic inflammatory milieu and high titers of auto-antibodies in lupus, decrease disease symptoms and prolong survival in the NZBxNZWF1 mouse model of lupus. In our initial findings we report that treatment of lupus-prone NZBxNZWF1 mice with small molecule inhibitor of Tyk2Jak1 significantly lowers the pathological auto-antibody production. The treatment also lead to a drop in the number of germinal centers in the spleen NZBxNZWF1 mice as well as a decrease in spleen weights. Over all, the treatment has shown potential for significantly improving the disease pathology in NZBxNZWF1 mouse model of lupus. We are in the process of performing experiments for the next phase of the proposal.

Subject Categories:

  • Medicine and Medical Research
  • Biochemistry

Distribution Statement: